Cathryn Jane Poulton

Dr. Cathryn Jane Poulton


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJustin Szot
Justin Szot
HCHartmut Cuny
Hartmut Cuny
EMElla M.M.A. Martin
Ella M.M.A. Martin
DSDelicia Z. Sheng
Delicia Z. Sheng
KIKavitha Iyer
Kavitha Iyer
SDSally Dunwoodie
Sally Dunwoodie
Nicotinamide adenine dinucleotide (NAD) is essential for embryonic development. To date, biallelic loss-of-function variants in 3 genes encoding nonredundant enzymes of the NAD de novo synthesis pathway — KYNU, HAAO, and NADSYN1 — have been identified in humans with congenital malformations defined as congenital NAD deficiency disorder (CNDD). Here, we identified 13 further individuals with biallelic NADSYN1 variants predicted to be damaging, and phenotypes ranging from multiple severe malformations to the complete absence of malformation. Enzymatic assessment of variant deleteriousness in vitro revealed protein domain–specific perturbation, complemented by protein structure modeling in silico. We reproduced NADSYN1-dependent CNDD in mice and assessed various maternal NAD precursor supplementation strategies to prevent adverse pregnancy outcomes. While for Nadsyn1+/– mothers, any B3 vitamer was suitable to raise NAD, preventing embryo loss and malformation, Nadsyn1–/– mothers required supplementation with amidated NAD precursors (nicotinamide or nicotinamide mononucleotide) bypassing their metabolic block. The circulatory NAD metabolome in mice and humans before and after NAD precursor supplementation revealed a consistent metabolic signature with utility for patient identification. Our data collectively improve clinical diagnostics of NADSYN1-dependent CNDD, provide guidance for the therapeutic prevention of CNDD, and suggest an ongoing need to maintain NAD levels via amidated NAD precursor supplementation after birth.

18 September 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
CPCathryn Jane Poulton
Cathryn Jane Poulton
DGDylan Gration
Dylan Gration
KMKevin Murray
Kevin Murray
GBGareth Baynam
Gareth Baynam
AHAnne Halbert
Anne Halbert

9 December 2017 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
CPCathryn Jane Poulton
Cathryn Jane Poulton
GBGareth Baynam
Gareth Baynam
CYClarissa Yates
Clarissa Yates
HAHamid Alinejad‐Rokny
Hamid Alinejad‐Rokny
SWSimon Williams
Simon Williams
JHJulian Ik‐Tsen Heng
Julian Ik‐Tsen Heng
Background: Pallister‐Killian syndrome (PKS) is a rare multisystem developmental syndrome usually caused by mosaic tetrasomy of chromosome 12p that is known to be associated with neurological defects.Methods: We describe two patients with PKS, one of whom has bilateral perisylvian polymicrogyria (PMG), the other with macrocephaly, enlarged lateral ventricles and hypogenesis of the corpus callosum. We have also summarized the current literature describing brain abnormalities in PKS.Results: We reviewed available cases with intracranial scans (n = 93) and found a strong association between PKS and structural brain abnormalities (77.41%; 72/93). Notably, ventricular abnormalities (45.83%; 33/72), abnormalities of the corpus callosum (25.00%; 18/72) and cerebral atrophy (29.17%; 21/72) were the most frequently reported, while macrocephaly (12.5%; 9/72) and PMG (4.17%; 3/72) were less frequent. To further understand how 12p genes might be relevant to brain development, we identified 63 genes which are enriched in the nervous system. These genes display distinct temporal as well as region‐specific expression in the brain, suggesting specific roles in neurodevelopment and disease. Finally, we utilized these data to define minimal critical regions on 12p and their constituent genes associated with atrophy, abnormalities of the corpus callosum, and macrocephaly in PKS.Conclusion: Our study reinforces the association between brain abnormalities and PKS, and documents a diverse neurogenetic basis for structural brain abnormalities and impaired function in children diagnosed with this rare disorder.

27 August 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
CPCathryn Jane Poulton
Cathryn Jane Poulton
DADimitar Azmanov
Dimitar Azmanov
VAVanessa Atkinson
Vanessa Atkinson
JBJohn Beilby
John Beilby
LELisa Ewans
Lisa Ewans
GBGareth Baynam
Gareth Baynam

1 May 2019 in Gene
Verified
Journal Article
Closed access
CPCathryn Jane Poulton
Cathryn Jane Poulton
GPG. Pathak
G. Pathak
KMK. Mina
K. Mina
TLTimo Lassmann
Timo Lassmann
DAD.N. Azmanov
D.N. Azmanov
GBG. Baynam
G. Baynam

1 December 2019 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
KJKatrine M Johannesen
Katrine M Johannesen
DMDiana Mitter
Diana Mitter
RJRobert Marek Janowski
Robert Marek Janowski
CRChristian Roth
Christian Roth
JTJoseph Toulouse
Joseph Toulouse
RMRikke S. Møller
Rikke S. Møller
Objective The study is aimed at widening the clinical and genetic spectrum and at assessing genotype-phenotype associations in QARS encephalopathy. Methods Through diagnostic gene panel screening in an epilepsy cohort, and recruiting through GeneMatcher and our international network, we collected 10 patients with biallelic QARS variants. In addition, we collected data on 12 patients described in the literature to further delineate the associated phenotype in a total cohort of 22 patients. Computer modeling was used to assess changes on protein folding. Results Biallelic pathogenic variants in QARS cause a triad of progressive microcephaly, moderate to severe developmental delay, and early-onset epilepsy. Microcephaly was present at birth in 65%, and in all patients at follow-up. Moderate (14%) or severe (73%) developmental delay was characteristic, with no achievement of sitting (85%), walking (86%), or talking (90%). Additional features included irritability (91%), hypertonia/spasticity (75%), hypotonia (83%), stereotypic movements (75%), and short stature (56%). Seventy-nine percent had pharmacoresistant epilepsy with mainly neonatal onset. Characteristic cranial MRI findings include early-onset progressive atrophy of cerebral cortex (89%) and cerebellum (61%), enlargement of ventricles (95%), and age-dependent delayed myelination (88%). A small subset of patients displayed a less severe phenotype. Conclusions These data revealed first genotype-phenotype associations and may serve for improved interpretation of new QARS variants and well-founded genetic counseling.